ð»ââïžãããããããã«ãŒããªãŒãç®ã«è¯ããšèšãããŠé·ãããæè¿ã§ã¯ã«ãã€ã³ã泚ç®ãéããŠãããããã®ããã
ðŠãããã ããããŸãããã§ããããã£ãŠæ¬åœã«ã©ã£ã¡ãå¹ãã®ãç§åŠçã«èšŒæãããŠãã®ããªïŒäž¡æ¹å¹ããªãïŸïŸïœžãåãå
¥ããããã©ïŒã
ð»ââïžããããªãæåãå¹èœãç§åŠçãªç 究ãå«ããŠè©³ããèŠãŠã¿ãããã®ãã
ðŠã倧è³æã ãïŒïŸïœš~ããªãã ãã¯ã¯ã¯ã¯ããŠããïŒã
ð»ââïžãã«ãŒããªãŒãšðŠã«ãã€ã³ïŒç§åŠãè£ä»ããç®ã®å¥åº·æŠç¥
ãã«ãŒããªãŒãšã«ãã€ã³ã¯ã©ã¡ããç®ã«è¯ããšèšãããŠããããããããã«ç¹åããå¹èœãããããããç§åŠçãªç 究ããããããããç®ã®å¥åº·ç¶æã«æçã§ããããšãæ¯æãããŠãããããä»æ¥ã¯ãã®æåãå¹èœããããŠç§åŠçæ ¹æ ã«ã€ããŠè©³ãã解説ãããã
ð»ââïžãã«ãŒããªãŒïŒã¢ã³ãã·ã¢ãã³ãšãã®ç§åŠçå¹æ
æåãšå¹èœ
- ã¢ã³ãã·ã¢ãã³ïŒãã«ãŒããªãŒã®äž»æåã§ã網èã®è¡æµãæ¹åããèŠèŠæ©èœããµããŒãããã
- æé žåäœçšïŒçŽ°èãé žåã¹ãã¬ã¹ããå®ããç®ã®èåãç²åŽãé²ãã
- å€éèŠåã®æ¹åïŒäžéšã®ç 究ã§ã¯ãã¢ã³ãã·ã¢ãã³ãæé å¿ïŒæéã§ç®ãæ £ããèœåïŒãå©ããããšã瀺åãããŠããã
ç§åŠçç 究
- èŠèŠæ©èœæ¹åã®ç 究
è«æã«ãããšããã«ãŒããªãŒç±æ¥ã®ã¢ã³ãã·ã¢ãã³ãçŒç²Ÿç²åŽã軜æžããç®ã®è¡æµãæ¹åããããšã確èªãããŠããã
äŸïŒ2012幎ã®ããç 究ã§ã¯ããã«ãŒããªãŒãšãã¹ãæåãã被éšè ãé·æéã®ããžã¿ã«äœæ¥åŸãç®ã®ç²åŽã軜æžããããšããçµæãåºãŠããã - æé
žåã®äœçš
æé žåæåãšããŠã®ã¢ã³ãã·ã¢ãã³ã¯ãããªãŒã©ãžã«ã«ãäžåããç®ã®çµç¹ãä¿è·ããåããããšãããŠããã
ðŠã«ãã€ã³ïŒç®ã®ãã£ã«ã¿ãŒãšé»æéšä¿è·ã®ãšãã¹ããŒã
æåãšå¹èœ
- é»æè²çŽ ïŒã«ãã€ã³ã¯é»æéšïŒç¶²èã®äžå¿ïŒã«èç©ãããã«ãŒã©ã€ãã玫å€ç·ããç®ãä¿è·ãã倩ç¶ãã£ã«ã¿ãŒã
- æççäœçšïŒççãæããå¹æãæåŸ ãããŠãããç®ã®çŸæ£ãªã¹ã¯ãäœæžããã
- å 霢é»æå€æ§çïŒAMDïŒã®äºé²ïŒã«ãã€ã³ãäžè¶³ãããšAMDã®ãªã¹ã¯ãé«ãŸãã
ç§åŠçç 究
- ã«ãã€ã³ã®å
ä¿è·äœçš
2016幎ã®ããç 究ã§ã¯ãã«ãã€ã³æåãç®ã®é»æè²çŽ å¯åºŠãé«ãããã«ãŒã©ã€ãã«ãããã¡ãŒãžã軜æžããããšã確èªãããŠããã - AMDäºé²ã®ãšããã³ã¹
倧èŠæš¡ç 究ãAREDS2ïŒAge-Related Eye Disease Study 2ïŒãã«ãããšãã«ãã€ã³ã®è£çµŠãå 霢é»æå€æ§çã®é²è¡ãæããå¹æããããšå ±åãããŠããã
ð»ââïžðŠãã«ãŒããªãŒãšã«ãã€ã³ãäž¡æ¹æãå®è·µæ³
ç§åŠçã«èŠãŠãããã«ãŒããªãŒãšã«ãã€ã³ã®å¹æã¯è£å®çãããäžæ¹ãéžã¶ã®ã§ã¯ãªããäž¡æ¹ãåãå ¥ããããšã§ç®ã«å¯Ÿããå€è§çãªãµããŒããå¯èœã«ãªããããã
æ¥åžžç掻ã§ã®åãå ¥ãæ¹ïŒ
- æé£ïŒãã«ãŒããªãŒå ¥ããšãŒã°ã«ããæãã
- æŒé£ã»å€é£ïŒã»ãããèãã±ãŒã«ã®ãµã©ããã¹ãŒããã¡ãã¥ãŒã«å ããã
- ãã¶ãŒãïŒãã«ãŒããªãŒã®ã¿ã«ãã楜ããã
- ãµããªã¡ã³ãïŒäž¡æ¹ããã©ã³ã¹ããè£ãããã®ãµããªãå©çšããã
ð»ââïžãŸãšãïŒç§åŠãšæ¥åžžã®èå
ãã«ãŒããªãŒã¯èŠèŠæ©èœã®ç¶æãšæé žåäœçšã«åªããã«ãã€ã³ã¯ç®ã®ãã£ã«ã¿ãŒåœ¹ãšããŠå 霢ã«ããç®ã®çŸæ£ãé²ãåããããç§åŠçç 究ããããã®å¹èœãæ¯æããŠãããæ¥åžžç掻ã«åãå ¥ãã䟡å€ã倧ãã«ãããããã
ðŠãããŸãããïŸïŸïœžããããããã«ãŒããªãŒãšã«ãã€ã³ãäž¡æ¹åãããšã«ãããïŒãã¶ãŒãããµã©ãããç®ã«è¯ãã£ãŠæããšããçŸå³ããæãããïŒã
ð»ââïžãããããããå¥åº·çãªæ®ããã®ç§èš£ããã®ãå
±ã«ç®ã倧åã«ããŠããããããã
ãé©æãç·é¡140äžååã®FXã·ã°ãã«ãâãã£ã2äžåâã§æ°žä¹ å ¥æïŒïŒ
- ðSODA(FREE)ðïŒðç¡æåå ã§ãããæ軜ã·ã°ãã«ãã£ã³ãã«ðµ
- ð¥SODA(MB GOLD)ïŒéååŒã®é«ç²ŸåºŠã·ã°ãã«ãäžææ°åãã«ã®ç Žå£åãæ·¡ã ãšããªãã®ã¯å§å·»ã
- ð¥SODA(ICT THE BEST)ïŒICTãšããŠçè«ã®ç©¶æ¥µè³é«ã®ã·ã°ãã«ãé±é500pipsã¯æ¥åžžè¶é£¯äºã
- ð¯SODA(DG)ïŒé »åºŠã¯å°ãªããã©ç²ŸåºŠæ矀ã®ã¹ãã€ããŒãã¬ãŒãð«âš
- ðSODA(UK)ïŒãšããŸããã¯é貚ãããŸããïŒäžèœåãªãŒã«ã©ãŠã³ããŒã·ã°ãã«ðâš
- ð§ SODA(PK)ïŒSmartTradeçè«ã§ç¥çã«ãã¬ãŒãðâš
ãããæ匷ã®åžé£ãã·ã°ãã«é
ä¿¡è
ãšã®å
±åã®ããšãåžžåã·ã°ãã«ãçæ§ã®ããšã«äžæ°é
ä¿¡ïŒ
ãŸãã¯ç¡æã§é«ç²ŸåºŠãèªãæ匷ã·ã°ãã«ãã芧ãã ããã
ð¡ð€äºå©ãµãŒãã¹å ¥äŒã®ãæ¡å ð€ð¡
- å ¥äŒäŸ¡æ Œã¯ããããããäžåŸ Â¥2äžåïŒæãåãïŒ ã§ãã
- äžåºŠã®ãæ¯æãã§äžç涯䜿ããŸãïŒ
- ð³ãæ¯æãæ¹æ³ïŒPayPayãããŒééãPayPayæ¯èŸŒã«å¯Ÿå¿ããŠããŸãðŠ
ð§ããããã質åQïŒAâš
- â³ã·ã°ãã«ã®é
ä¿¡æéã¯ãã€ãŸã§ã§ããïŒ
â å ¥äŒããç¡å¶éã§ãã - ð»VPSã¯å¿
èŠã§ããïŒ
â EAãåããå Žåã¯VPSãå¿ èŠã§ããæé¡10ãã«ã§å©çšã§ããå®å®ããVPSããæ¡å ããŠããŸãã - â ïžæ³çãªãªã¹ã¯ã¯ãããŸããïŒ
â FXååŒã«ã¯ãªã¹ã¯ã䌎ããŸããåœã°ã«ãŒãã®ã·ã°ãã«ã¯åèæ å ±ãšããŠæäŸãããŠããŸãã®ã§ãèªå·±è²¬ä»»ã§ã®ååŒããé¡ãããŸãã
ãæ°è»œã«çžè«ãã ãã
ããŸãã¯ã©ããªã®ããèŠããŠã¿ãããã1æã ãå šæ©èœã䜿ã£ãŠã¿ããããªã©ããè©Šããªã©ããããããèŠæã«ãå¿ãããŸãããŸãã¯ãæ°è»œã«ã¡ãã»ãŒãžãéã£ãŠã¿ãŠãã ããã